Wall Street Zen Downgrades Thermo Fisher Scientific (NYSE:TMO) to Hold

Thermo Fisher Scientific (NYSE:TMO) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

TMO has been the subject of a number of other research reports. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. BMO Capital Markets cut Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday. HSBC upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Finally, Royal Bank Of Canada increased their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $624.64.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $610.97 on Friday. The firm has a market capitalization of $225.90 billion, a price-to-earnings ratio of 32.87, a P/E/G ratio of 2.55 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a fifty day moving average of $580.40 and a 200 day moving average of $518.56. Thermo Fisher Scientific has a 52-week low of $435.27 and a 52-week high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter last year, the firm posted $4.28 EPS. The company’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, research analysts expect that Thermo Fisher Scientific will post 25.13 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the sale, the vice president owned 14,784 shares of the company’s stock, valued at approximately $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 275 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. The trade was a 0.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently modified their holdings of TMO. California State Teachers Retirement System raised its position in Thermo Fisher Scientific by 49,331.5% during the 2nd quarter. California State Teachers Retirement System now owns 282,654,735 shares of the medical research company’s stock valued at $141,711,778,000 after purchasing an additional 282,082,924 shares during the last quarter. J. Stern & Co. LLP grew its position in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. BlackRock Inc. purchased a new stake in Thermo Fisher Scientific in the second quarter worth $15,501,867,000. State Street Corp boosted its holdings in Thermo Fisher Scientific by 1.4% in the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after acquiring an additional 229,630 shares in the last quarter. Finally, Corient Private Wealth LP purchased a new position in Thermo Fisher Scientific during the 2nd quarter valued at $382,547,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.